Hepatitis Vaccine Market: Increasing incidence of Autoimmune Diseases Raise Hepatitis Disorder Fears Globally
Hepatitis Vaccine Market |
Hepatitis is a major cause of healthcare
burden in both developed and developing countries. Patients with autoimmune
disorders are contributing to the rise in hepatitis prevalence. This steady
growth is being aided by an aging population and varying societal behavior.
Rising viral infections such as type A, B, C, D, E, and possibly G are the
leading causes of hepatitis. Chronic hepatitis can be caused by hepatitis B and
C. Acute hepatitis A symptoms include fatigue, flu-like symptoms, and dark
urine, whereas chronic hepatitis symptoms are mild and non-specific.
Hepatitis A vaccine is a vaccine designed to
protect against the hepatitis A virus. The Hepatitis A vaccine is available for
long-term HAV infection prevention. The minimum age for HAV vaccination is one
year. The classification of Hepatitis A Vaccine includes Inactivated Vaccine
and Live Attenuated Vaccine, with Inactivated Vaccine accounting for
approximately 70.8 percent of sales in 2017, with the proportion increasing
from 2013 to 2018. The end-user segment, type segment, and geographical
landscapes are all examined in the hepatitis
vaccine market analysis. This study identifies rising immunization
awareness in low- and middle-income countries as one of the primary factors
driving hepatitis vaccine market growth over the next few years.
The number of hepatitis B cases has
skyrocketed in recent years. Furthermore, the rise in the population increased
awareness among people for better healthcare facilities, and innovations in the
type of medications with higher efficiency are driving the market growth. There are
new vaccines on the market, such as recombinant DNA vaccines made by inserting the hepatitis B virus.
The market is further subdivided by dose into the 3-dose schedule, 2-dose schedule, and alternate schedule, with the 3-dose
schedule expected to achieve the highest absolute $ opportunity growth in the
market due to infants being at high risk of developing a lifelong infection if
exposed to the hepatitis B virus. Furthermore, the alternate schedule
recommended for adolescents is expected to grow significantly due to their
potentially experimental lifestyle choices, which place them at high risk of
becoming infected with the hepatitis B virus. The market is divided into end-users, which include hospitals, clinics, and others.
According to Vision gain, oral antivirals
will be the most important segment of the hepatitis treatment and vaccines
market in 2022. This growth will be fueled by the approval of direct-acting
antivirals for the treatment of hepatitis C over the next ten years. Interferon
therapies, which are used to treat hepatitis B and C, accounted for 34.0
percent of the hepatitis market in 2011. However, the market impact of these
therapies will diminish as more patients with hepatitis C are switched to oral
antivirals, particularly after the middle of the decade.
Comments
Post a Comment